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Diabetes mellitus is the most common and rapidly growing
cause of end-stage renal disease. A classic hallmark of
diabetes pathology is the activation of the intrarenal
renin–angiotensin system (RAS), which may lead to
hypertension and renal tissue injury, but the mechanism of
RAS activation has been elusive. Recently, we described the
intrarenal localization of the novel metabolic receptor GPR91
and established some of its functions in diabetes. These
include the triggering of renin release in early diabetes via
both vascular (endothelial) and tubular (macula densa) sites
in the juxtaglomerular apparatus as well as the activation of
MAP kinases in the distal nephron-collecting duct, which are
important signaling mechanisms in diabetic nephropathy (DN)
and renal fibrosis. GPR91 is a cell surface receptor for succinate
and during the past few years it has provided a new paradigm
for the mechanism of cell stress response in many organs.
Beyond its traditional role in the tricarboxylic acid cycle,
succinate now has an unexpected hormone-like signaling
function, which may provide a feedback between local tissue
metabolism, mitochondrial stress, and organ functions.
Succinate accumulation in the local tissue environment and
GPR91 signaling appear to be important early mechanisms
by which cells detect and respond to hyperglycemia and
trigger tissue injury in DN. Also, the distal nephron-collecting
duct system, which is the major source of (pro)renin in
diabetes and has the highest level of GPR91 expression in the
kidney, may have an important, active, and early role in the
pathogenesis of DN in contrast to the existing glomerulus-
centric paradigm.
Kidney International (2010) 78, 1214–1217; doi:10.1038/ki.2010.333;
published online 22 September 2010
KEYWORDS: diabetic nephropathy; renin–angiotensin system
SYSTEMIC VERSUS LOCAL EFFECTS OF HIGH GLUCOSE
The incidence of diabetes mellitus is rapidly rising to
epidemic levels worldwide and diabetic nephropathy (DN)
is the leading cause of end-stage renal disease in developed
countries.1,2 DN is characterized by the initial thickening of
glomerular and tubular basement membranes and mesangial
matrix expansion, slowly progressing into glomerulosclerosis
and tubulointerstitial fibrosis. These morphological changes
correlate strongly with the clinical symptoms, which
include microalbuminuria, proteinuria, hypertension, and
kidney failure.1,2 The pathomechanism of DN is complex,
with a number of metabolic, inflammatory, and hemody-
namic factors and multiple cell types involved, including
mesangial and endothelial cells, podocytes, the tubular
epithelium, interstitial cells, and vascular smooth muscle
cells.2,3 These factors can activate a wide array of intracellular
signaling pathways, transcription factors, and cytokines
which were reviewed recently.1–5 As a result, the abnormal
transcription and translation of various genes lead to
augmented production of extracellular matrix, and ultimately
tissue fibrosis and sclerosis.1–3 Hemodynamic factors include
glomerular hypertension, hyperfiltration, peritubular capil-
lary rarefaction, and the activation of the renin–angiotensin
(Ang) system (RAS).1,2,6–8 RAS inhibitors can slow down the
progressive decrease in glomerular filtration rate, reduce
proteinuria, and microalbuminuria, prevent transition to
advanced disease stages, reduce cardiovascular mortality,
and morbidity, and even cause regression of some pathology
and proteinuria.1,6–8 However, the nature of RAS activation
in diabetes has been controversial.7 The current paradigm,
the so-called ‘tubular hypothesis of glomerular filtration’,9
argues that the two hallmarks of early changes, glomerular
hyperfiltration and renin activation, originate from the
primary effects of glucose on proximal tubule salt reabsorp-
tion, which in turn activate macula densa-mediated feedback
mechanisms. Nevertheless, the development of diabetes-
induced glomerular hyperfiltration was intact or even
augmented in adenosine A(1)-receptor-deficient mice that
lack tubuloglomerular feedback, demonstrating that
the tubuloglomerular feedback mechanism could not be
the major cause of the development of hyperfiltration.10,11
The discovery of the G-protein-coupled receptor, GPR91,12
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which is activated by the citric acid (tricarboxylic acid) cycle
intermediate succinate established a novel mechanism of
RAS activation. Intravenous injection of succinate into rats
and wild-type mice induced hypertension within 1–2min
via renin release and the RAS, and this response was
abolished in GPR91-deficient mice.12 On the basis of these
findings, our laboratory identified a new, direct link between
diabetic hyperglycemia and renin release,13–15 the rate-
limiting step of RAS activation. The elevations in renal and
plasma renin and prorenin that were observed in diabetic
mice were abolished in diabetic GPR91 knockout mice.13
Using a freshly dissected in vitro microperfused juxtaglo-
merular apparatus (JGA) preparation, which is free of
systemic influences, we found GPR91-mediated renin release
1–2min after high glucose or succinate administration.13 The
paracrine signaling mechanism involved increases in macula
densa and endothelium-derived prostaglandin E2 and NO
synthesis and release mediated by intracellular Ca2þ (in
endothelium) and mitogen-activated protein kinases p38 and
pERK1/2 (in macula densa).13,14 Prostaglandin E2 via
paracrine signaling caused increased renin synthesis and
release from adjacent juxtaglomerular cells and RAS activa-
tion. Prostaglandin E2 and NO also caused afferent arteriole
vasodilatation, which may contribute to glomerular hyperfil-
tration in early DN.13 Therefore, it appears that local effects
of hyperglycemia are of key importance in triggering RAS
activation and glomerular hyperfiltration, the two renal
hallmarks of early diabetes.
MITOCHONDRIAL STRESS, SUCCINATE ACCUMULATION,
GPR91 ACTIVATION
Succinate accumulation and GPR91 signaling are early and
potentially important events in the diabetic kidney. Succinate is
normally present in the mitochondria as part of the
tricarboxylic acid cycle (Figure 1) to produce adenosine
triphosphate, but it is also found in the systemic circulation
with mean plasma levels between 1–20mM.12,16,17 However, the
accumulation of succinate in mitochondria, cytosol, and the
extracellular environment has been observed in (patho)phy-
siological states when there is an imbalance between energy
demand and the food and oxygen supply.12,13,16,17 These
conditions include hypoxia, diabetes, and cancer.12,13,16–19
In addition to the ‘normal’ hypoxia (cortical pO2 values
are in the range of 40mmHg, and pO2 values in the renal
medulla are even lower20), hyperglycemia is associated with
further, marked reductions in renal oxygen tension and it
further overwhelms mitochondrial respiration.21 With time
oxidative stress develops, which shows strong association
with kidney disease and hypertension.22 The accumulation of
succinate and reactive oxygen species are both signs of
mitochondrial stress and the two are closely associated,
although to date the role of succinate has been largely
overlooked. Remarkably, the old work of Krebs and others in
the 1960s established that in multiple organs, even short
durations of hypoxia (5–30 s) cause a selective rise in tissue
succinate in sharp contrast to the fall in other tricarboxylic
acid cycle intermediates.23,24 Consistent with the elevated
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Figure 1 | Illustration of the altered mitochondrial metabolism in diabetes and resulting changes in cell function including the
role of GPR91. The accelerated glucose uptake, glycolysis, and TCA cycle leads to high metabolic rate and significant succinate
accumulation in the mitochondria, cytosol, and interstitium. Succinate transport mechanisms including dicarboxylate carriers and organic
anion transporters for both the mitochondrial and plasma membranes are well established.48–50 GPR91 signaling may be involved in the cell
stress response to hypoxia and hyperglycemia leading to the overactivation of normally protective signaling pathways and pathology.
Abbreviations: EPO, erythropoietin; GLUT1, glucose transporter-1; HIF, hypoxia inducible factor; RAS, renin–angiotensin system; TCA,
tricarboxylic acid; VEGF, vascular endothelial growth factor.
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succinate levels in hypoxia, we measured 1–2 orders of
magnitude higher levels of succinate in the urine and kidney
homogenates of diabetic animals 1 week after streptozotocin
injection, compared with controls.13 Elevated circulating
succinate levels were found in rodent models of hypertension
and metabolic disease, however plasma succinate levels were
reported to be less informative in human hypertensive or
diabetic patients.17
During the past 5 years, 18 new papers in high profile
journals described this emerging topic, the role of GPR91 in
diverse organs, such as adipose tissue,25 liver,26 immune
system,27 bone marrow,28 retina,29 and kidney.12–15 GPR91-
dependent pathologies in the retina29 and kidney,12–15 suggest
that GPR91 may be a molecular link between the two most
common diabetic complications, diabetic nephropathy and
retinopathy. The role of the hypoxia-inducible (transcription)
factor and the hypoxia response genes including the vascular
endothelial growth factor in diabetic nephropathy is a hot
topic.30–33 As hypoxia-inducible factor is known to be
succinate dependent,34 GPR91 signaling may be involved in
the cellular responses to hypoxia particularly in diabetes. The
recent findings that succinate via GPR91-stimulated vascular
endothelial growth factor-mediated neovascularization in the
retina,29 as well as hematopoiesis in the bone marrow28
support this hypothesis. GPR91-mediated overactivation of
RAS (Figure 1) and other signaling systems (mitogen-
activated protein kinases p38, ERK1/2, and COX-2)13,14
however, may ultimately result in renal fibrosis.35–38
ROLE OF THE DISTAL NEPHRON-COLLECTING DUCT
Another important part of our novel concept is that the distal
nephron-collecting duct (CD) system has an important,
active, and early role in the pathogenesis of DN, in contrast
to the existing glomerulus-centric paradigm.2–5 This is based
on the predominant localization of GPR91 in the distal
nephron-CD system39 in addition to its expression in the
glomerulus,13 and our recent discovery that the connecting
tubule-CD, a newly recognized key anatomical site of RAS in
pathological states40,41 is the major source of (pro)renin in
diabetes.15,42 Therefore, in addition to the JGA, which is the
classical location of renin synthesis and release, the connect-
ing tubule-CD is another intrarenal site, wherein the
succinate receptor GPR91 is associated with renin produc-
tion. As these two locations are in close proximity to each
other in the renal cortex, future studies will benefit from
using direct imaging approaches. Using multiphoton fluor-
escence microscopy, we established the quantitative imaging
of basic functions in renal (patho)physiology in the intact
whole kidney including renin granule content, release, and
tissue renin activity.43–46 This experimental approach can
directly visualize the renin-expressing JGA and the cortical
CD in the intact, living kidney.43–46 (Pro)renin immuno-
fluorescence in Figure 2 illustrates the significant amount of
(pro)renin synthesis in the diabetic connecting tubule-CD
compared with the very low (pro)renin levels in these tubule
segments in the normal kidney as described before.40–42,46
Also, in contrast to the few renin-producing cells of the JGA,
the great number of principal cells of the connecting tubule-
CD are a major source of (pro)renin in the diabetic kidney
(Figure 2).
It should be noted that although diabetes is associated
with the activation of the intrarenal RAS, plasma renin levels,
and activity are paradoxically low.1,7,42 However, one hall-
mark of diabetes is the high plasma prorenin, which is mainly
of CD origin.42 As described above, in early diabetes GPR91
activation may trigger JGA renin release (the primary source
of active renin) and subsequent local Ang II production.
Importantly, Ang II has negative feedback on JGA renin,
whereas it activates CD prorenin production.41,42 CD
prorenin may then be released to cause local intrarenal or
systemic pathological actions at the recently identified and
characterized (pro)renin receptor,47 or may be activated to
generate local Ang II in the face of JGA renin suppression.
This theory, which is still a ‘work in progress’, may help
explain the paradox of low plasma renin but high prorenin
and activated intrarenal RAS in diabetes.
CONCLUSION
The recent studies on succinate and GPR91 identified novel
cellular and (patho)physiological detector mechanisms,
signaling pathways that may have important roles in diabetes
pathology in many organs. Future work on this emerging
topic may provide clinically important information that can
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Figure 2 | Immunofluorescence labeling of (pro)renin (green)
in a type 2 diabetic db/db mouse kidney. Methods and
materials were the same as described before.42 An area of the
renal cortex is shown, wherein two connecting tubules (CNT1–2)
join together to form the CCD. Nuclei are stained blue with
4’,6-diamidino-2-phenylindole. A few cells of the JGA are shown
next to the glomerulus. In contrast to the JGA, intense (pro)renin
labeling was found in most cells of the CNT–CCD (principal cells),
whereas a few cells were renin negative (intercalated cells).
Abbreviations: CCD, cortical collecting duct; G, glomerulus; JGA,
juxtaglomerular apparatus.
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be used to develop new drugs (novel GPR91 inhibitors) and
diagnostic approaches (urinary succinate) for the more
effective treatment and diagnosis of diabetic complications,
and potentially other hypoxia-related diseases, including
renovascular hypertension and chronic kidney disease.
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